Evaluate Ltd secures additional investment from Hg
Hg, the Manager of HgCapital Trust plc ("HGT"), today announces an additional investment into Evaluate Ltd., a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry. The terms of the transaction are not disclosed.
HGT, whose shares are listed on the London Stock Exchange, gives private and institutional investors the opportunity to participate in all Hg's investments.
The transaction will result in HGT investing approximately £8.1 million in Evaluate, alongside other institutional clients of Hg. This transaction represents an uplift on HGT's current investment in Evaluate of £3.1 million (40%) or 1 pence per share over the carrying value of £7.7 million in the Net Asset Value ("NAV") of HGT at 31 March 2020.
Note that these figures only relate to HGT's share of Hg's overall investment in Evaluate.
HGT's liquid resources available for future deployment are estimated to be £126.8 million (13% of the 31 March pro-forma NAV of £968 million). The investment will reduce HGT's outstanding commitments to invest in Hg transactions to approximately £908 million.
Evaluate Ltd. secures additional investment from Hg to drive further growth and expansion
Healthcare technology leader Dr. Sati Sian to be appointed as Chair
London, UK - 3 August 2020. Evaluate Ltd., a leading provider of commercial intelligence and predictive analytics to the pharmaceutical industry, today announces that it has secured additional investment from Hg, Europe's leading software investor.
Hg will now become the majority shareholder in Evaluate. Hg's backing will help Evaluate to continue to build out capabilities that support pharmaceutical portfolio optimisation and R&D productivity, accelerating investment in innovation and data science capabilities. It will also enable options for further expansion. As part of the transaction, Jonathan de Pass, Founder of Evaluate, will remain a significant shareholder and will continue to guide the business as a Director on the Board of Evaluate.
Evaluate is also pleased to announce that Dr. Sati Sian will be appointed as Chair. Dr. Sian is an experienced and proven leader in Evaluate's sector, bringing over 30 years of global experience in healthcare information, software and services. Dr. Sian joins Evaluate after serving as CEO of Allocate Software between 2015 and 2018, and prior to that was Senior VP for Global Technology and Operations at IMS Health.
Jonathan de Pass, Founder of Evaluate, said: "Hg first invested in Evaluate in 2016. Since then, the business has grown and scaled at a pace and in a manner that simply would not have been feasible without their support. Given this current momentum and the excellent teamwork between Evaluate and our Hg colleagues, I could not think of a better partner with which to continue this journey. I am also delighted to welcome Dr. Sian, an exceptional leader in healthcare technology, as we embark on a truly exciting future for the business."
Deborah Kobewka, CEO at Evaluate, said: "I'm thrilled that Hg will become the majority shareholder at Evaluate. It shows confidence in the company's trajectory and allows us to drive the business forward to new levels of growth and expansion, which only increases the value and service Evaluate delivers to clients. The opportunities ahead for Evaluate and our clients are greater than ever, especially as we push further into predictive analytics to revolutionise the pharmaceutical industry's approach to strategic portfolio optimisation."
David Issott, Partner at Hg, said: "What Deborah and her team have built over the last few years is a truly exceptional business, offering best-in-class products with the outstanding service its clients demand. Evaluate's recent performance through the Covid-19 crisis has been nothing short of astonishing and is a testament to the strength of the team. We're delighted to continue to partner with Jonathan de Pass in backing the business, in a bigger and more meaningful way than ever before."
Dr. Sati Sian, Chair at Evaluate, said: "Evaluate today has an incredibly strong team that is building on the business' unique offerings with a powerful set of new capabilities that leverage new technology and unparalleled information assets. I am excited to join the business and support the team to bring innovation to its clients and continue its growth through this next phase."
For further details:
Hg
Laura Dixon +44 (0)20 7089 7888
Brunswick
Samantha Chiene +44 (0)207 404 5959
About HgCapital Trust plc
HgCapital Trust plc, whose shares are listed on the London Stock Exchange (ticker: HGT.L), gives investors exposure through a liquid vehicle to a portfolio of high-growth private companies in the software and services sector. The selection of new investments and creation of value in these businesses are managed by Hg, an experienced and well-resourced private equity firm with a long-term track record of delivering superior risk-adjusted returns for its investors. For further details, please see www.hgcapitaltrust.com .
The contents of the Hg, HGT and Evaluate's websites are not incorporated into, and do not form part of, this announcement.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest directors dealings
- 13 hours ago Savannah Energy
- 14 hours ago Buccaneer Energy PLC
- 14 hours ago Savannah Energy
- 15 hours ago Carclo
- 15 hours ago Schroder Japan Growth Fund